The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Self-citationTau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“4–5 nmol/L CDK 9: 57 nmol/L CDK1: >1 μmol/L CDK2: >500 nmol/L (1, 88) PK Tmax 4.”
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
“CDK4/6 inhibitors have shown activity in breast cancer, particularly in combination with endocrine therapy (13, 23, 29).”
Self-citationA perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
“Among them, palbociclib, abemaciclib and ribociclib were approved by FDA as breast cancer therapy in this time frame [26].”
BackgroundTau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
“Practically, the loss of INK4 and CIP/KIP family proteins, as well as the amplification of CDK4/6, was observed clinically in BC [9,14].”
BackgroundInfluentialThe dormant cancer cell life cycle
Phan, T. G., & Croucher, P. I. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0263-0 · Cited by 576
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
“However, CIP and KIP proteins (particularly p21 and p27) have also been reported to promote S phase progression by forming stable complexes with CDK4/6 and cyclin D, which (1) stimulate CDK4/6 enzymatic function42,43 and (2) act as reservoirs that sequester p21 and/or p27 and thus allow unrestrained activity of CDK2 (…”
BackgroundInfluentialNon-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
Self-citationTurner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
Self-citationSpectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
“Taken together, the clinical profiles of the third-generation drugs (7, 19, 28, 29) suggest that they impact patient biology in unique ways.”
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang, M., Zhang, L., Hei, R., Li, X., Cai, H., Wu, X., Zheng, Q., & Cai, C. (2021) · PubMed Central · Cited by 397
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
“5), an inhibitor of CDKs 1, 2 and 4 failed in its initial Phase I study (Asghar et al., 2015).”
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Musa, J., Aynaud, M.-M., Mirabeau, O., Delattre, O., & Grünewald, T. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.244 · Cited by 322
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
“2C, D and E), consistent with other reports of CDK4/6 inhibitors (13).”
ResultCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
“Tumorigenic signals lead cyclin D to form complexes with either CDK4 or CKD6 leading to phosphorylation of the Retinoblastoma (RB) gene, which leads to the release of E2F to allow transcription of genes necessary for G1 to S phase transition [169,170].”
BackgroundBollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
Eifler, K., & Vertegaal, A. C. O. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.006 · Cited by 290
“This PDSM motif partly overlaps with the motif [S/T]Px[K/R], the preferential phosphorylation site for cyclin-dependent kinases (CDKs), which are key players in cell cycle progression [45].”
BackgroundCidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S. W., San Martin, M., Pop-Damkov, P., Su, N., Roamio Franklin, V. N., Sekhar Reddy Chilamakuri, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1853 · Cited by 288
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 287
“A recent study in patients with chronic lymphocytic leukemia (CLL) uncovered widespread upregulation of truncated mRNAs and proteins that were generated by increased IPA, suggesting that this is an epigenetic mechanism by which cancer cells can remodel their transcriptomes and proteomes without altering their genomes…”
BackgroundThe Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Self-citationThe CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
“A longstanding interest exists in CDKs as potential targets for anti-cancer drugs, although data from early trials testing pan-CDK inhibitors were generally negative, principally owing to substantial toxicities 9,10 .”
Self-citationCyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
“The CDK4/6–RB1 axis controls transition through the restriction point in the G1 phase of the cell cycle, and cancers frequently subvert the regulation of this axis to promote proliferation (1, 2).”
Self-citationStructural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis
Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.024 · Cited by 252
“html), reflecting the impact of early detection with biomarkers/medical check-ups, cancer prevention and novel therapeutics (protein kinase inhibitors [7] and humanized antibody therapies [8]).”
BackgroundHafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.05.005 · Cited by 250
“Also common are deficiencies in pRb function, which cause unregulated S phase entry, and deletion of the CDK4/6 inhibitor p16 (encoded by CDKN2A) (Asghar et al., 2015; Franco et al., 2014).”
BackgroundInfluentialTripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
“While the half-lives of ribociclib and palbociclib enable oncedaily, 3-weeks-on/1-week-off dosing (14), the PK/pharmacodynamic profile of abemaciclib favors twice-daily, continuous dosing (29, 70).”
InfluentialCyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M., Sun, H., Morton, G., Madzo, J., Chung, W., Khowsathit, J., Perez-Leal, O., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 222
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 220
“Temporal activation of these CDKs by the CAK complex ensures orderly progression within the cell cycle (Asghar et al., 2015).”
BackgroundCyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
“Over the past 20 years, a number of CDK inhibitors have been developed and successfully tested in clinical trials for different tumor types (37).”
BackgroundSirvent, J. A., & Lücking, U. (2017) · ChemMedChem · doi:10.1002/cmdc.201700044 · Cited by 213
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Finn, R. S., Liu, Y., Zhu, Z., Martin, M., Rugo, H. S., Diéras, V., Im, S.-A., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 201
“CDK4/6 activity and progression to the G1 phase are negatively regulated by the CDK4/6-interacting proteinkinase inhibitory protein (Cip-Kip) and by the inhibitor of the cyclindependent kinase 4 (INK4) families, typified by p16, the protein product of CDKN2A (16, 18).”
BackgroundInfluentialTargeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Fusco, G., Martinelli, C., Nuzzo, F., Pensabene, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186479 · Cited by 200
“The kinase activity of CDK4/6 is negatively regulated by two families of CDK inhibitors (CDKi), able to bind the ATP-binding pocket of CDK and to inhibit the downstream CDK4/6-mediated phosphorylation of Rb; this endogenous inhibition of CDK4/6 potently arrest cell cycle but requires functional Rb protein (Figure 1) […”
BackgroundCDK7 inhibitors as anticancer drugs
Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L., & Ali, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09885-8 · Cited by 200
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
“CDK4/6 inhibitors are known to inhibit cell cycle (Asghar et al., 2015) but also exert two biochemical effects that are potentially germane to tumor metabolism.”
InfluentialSelf-citationAn insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold
Cherukupalli, S., Karpoormath, R., Chandrasekaran, B., Hampannavar, G. A., Thapliyal, N., & Palakollu, V. N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.019 · Cited by 195
Geoerger, B., Bourdeaut, F., DuBois, S. G., Fischer, M., Geller, J. I., Gottardo, N. G., Marabelle, A., Pearson, A. D. J., Modak, S., Cash, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2898 · Cited by 190
“Hematologic AEs have also been associated with the CDK4/6 inhibitor palbociclib, suggesting an on-target effect for this class of drugs (23).”
BackgroundEndocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
Saatci, Ö., Huynh‐Dam, K., & Şahin, Ö. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02136-5 · Cited by 190
Lücking, U., Scholz, A., Lienau, P., Siemeister, G., Kosemund, D., Bohlmann, R., Briem, H., Terebesi, I., Meyer, K., Prelle, K., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700447 · Cited by 188
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Xue, Y., Meehan, B., Fu, Z., Wang, X. Q. D., Fiset, P. O., Rieker, R., Levins, C., Kong, T., Zhu, X., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08380-1 · Cited by 187
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
“The activation of CDK4 or CDK6 is driven by multiple factors, including the induction of D-type cyclins that are required for catalytic activity[5, 6].”
BackgroundSelf-citationNovel pyridine and pyrimidine derivatives as promising anticancer agents: A review
Albratty, M., & Alhazmi, H. A. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103846 · Cited by 179
Cell cycle regulators in cancer cell metabolism
Leal-Esteban, L. C., & Fajas, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165715 · Cited by 179
Martínez-Alonso, D., & Malumbres, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.009 · Cited by 179
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
“peutic targets in cancer after underwhelming results and unacceptable toxicity were seen with pan-CDK inhibitors such as flavopiridol (alvocidib) in the early 2000s [17].”
BackgroundInfluentialAdvances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 177
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
The Emerging Role of Cdk5 in Cancer
Pozo, K., & Bibb, J. A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.09.001 · Cited by 174
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Karakashev, S., Zhu, H., Yokoyama, Y., Zhao, B., Fatkhutdinov, N., Kossenkov, A. V., Wilson, A. J., Simpkins, F., Speicher, D., Khabele, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.095 · Cited by 174
“Indeed, phosphorylated CDC2 (also known as CDK1), a marker of G2-M checkpoint (Asghar et al., 2015), was also decreased by JQ1 alone or the combination compared to Olaparib alone (Figure 3A).”
BackgroundAnshabo, A. T., Milne, R. W., Wang, S., & Albrecht, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678559 · Cited by 174
Thill, M., & Schmidt, M. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793326 · Cited by 172
CRL4AMBRA1 is a master regulator of D-type cyclins
Simoneschi, D., Rona, G., Zhou, N., Jeong, Y.-T., Jiang, S., Milletti, G., Arbini, A. A., O’Sullivan, A., Wang, A. A., Nithikasem, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03445-y · Cited by 172
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“At present, the therapeutic focus has been on leveraging CDK4/ 6 inhibition to activate RB and limit tumor cell proliferation to delay disease progression.(127,128) Interesting to note, the pan-caner analysis of the CDK4/6 pathway showed that CDKN2A loss and RB1 loss were mutually exclusive in most cancers that lose t…”
BackgroundCDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Spring, L. M., Wander, S. A., Zangardi, M., & Bardia, A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0769-3 · Cited by 170
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J. E., Storrie-White, H., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E.-J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 156
“Conventional cytotoxic chemotherapy is highly effective in certain cancers but causes dose-limiting damage to normal proliferating cells, especially hematopoietic stem and progenitor cells (HSPCs).”
BackgroundInfluentialOshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082921 · Cited by 169
“The G2-M (G2M) checkpoint in cell cycle control mediates G2-M cell cycle transition through cyclin B-cdc2 (CDK1) complexes [3,4], and G2M regulation mediated by CDK1 is a critical factor in tumorigenic events [5].”
BackgroundRecent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
“The development of this non-selective compound was discontinued due to the low specificity for CDKs and narrow therapeutic window [17].”
BackgroundZeng, K., Li, W., Wang, Y., Zhang, Z., Zhang, L., Zhang, W., Xing, Y., & Zhou, C. (2023) · Advanced Science · doi:10.1002/advs.202301088 · Cited by 168
Wood, D. J., Korolchuk, S., Tatum, N. J., Wang, L.-Z., Endicott, J. A., Noble, M. E. M., & Martin, M. P. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.015 · Cited by 168
“In particular, a broad selectivity is thought to contribute to the dose-limiting toxicity that has led to the closure of a number of clinical programs (Asghar et al., 2015; Mariaule and Belmont, 2014; Whittaker et al., 2017).”
BackgroundCyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
Sonawane, Y. A., Taylor, M. A., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00150 · Cited by 155
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
“Partially because of dose-limiting toxicity that hinders their use, these pan-CDK inhibitors showed poor results [1].”
BackgroundThe application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 167
“Since CDK inhibitors were developed 20 years ago, CDK4/6 inhibitors have achieved great success in breast cancer [19, 20], and cell cycle therapy has gradually matured.”
BackgroundCircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
Wu, J., Jiang, Z., Chen, C., Hu, Q., Fu, Z., Chen, J., Wang, Z., Wang, Q., Li, A., Marks, J. R., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.033 · Cited by 164
RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy
Indovina, P., Pentimalli, F., Casini, N., Vocca, I., & Giordano, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4286 · Cited by 163
“For instance, previous studies have shown that the “cell cycle-mediated resistance” to chemotherapy can be overcome by an appropriately scheduled administration [136, 145].”
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
Role of the androgen receptor in triple-negative breast cancer.
Rampurwala, M. M., Wisinski, K. B., & O'Regan, R. M. (2016) · PubMed · Cited by 163
Au-Yeung, G., Lang, F., Azar, W. J., Mitchell, C., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C., Pearson, R. B., Mileshkin, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 146
“424 Although we observed a difference in the amplicon dependent sensitivity of CDK2 gene 425 suppression compared to pharmacological inhibition, dinaciclib remains a potent CDK2 426 inhibitor with single agent activity in CCNE1-amplified HGSC cell lines and is one of the 427 most clinically advanced CDK2 inhibitors (3…”
Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.
Darwiche, N. (2020) · PubMed Central · Cited by 163
Resistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 163
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
George, M. A., Qureshi, S., Omene, C. O., Toppmeyer, D., & Ganesan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693104 · Cited by 165
“Abemaciclib has five-foldmore potency for CDK4 than palbociclib or ribociclib (16, 35).”
BackgroundInfluentialMalorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
“In breast cancer, molecular alterations involving the CyclinD-CDK4/6-Rb pathway frequently occur [3] and strategies to target this pathway have recently been proven to be effective in patients with advanced breast cancer, particularly those with hormone receptor positive (HR+), HER2 negative (HER2neg) tumors [4].”
BackgroundTargeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N., Teng, M., Gray, N. S., & Johnstone, R. W. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 161
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 161
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
A review on the role of cyclin dependent kinases in cancers
Ghafouri-Fard, S., Khoshbakht, T., Hussen, B. M., Dong, P., Gassler, N., Taheri, M., Baniahmad, A., & Dilmaghani, N. A. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02747-z · Cited by 159
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., & Jiang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00487 · Cited by 159
“The cell cycle, the mechanism of cell division, is composed by four phases: the G1 phase, during which a cell begins to grow in size to be ready to DNA synthesis; the S phase (synthesis), during which cell synthesizes DNA; the G2 phase, during which a cell continues to grow to be ready for mitosis; the M phase (mitosi…”
BackgroundSoltan, O. M., Shoman, M. E., Abdel‐Aziz, S. A., Narumi, A., Konno, H., & Abdel‐Aziz, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113768 · Cited by 157
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 156
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Crozier, L., Foy, R., Mouery, B. L., Whitaker, R. H., Corno, A., Spanos, C., Ly, T., Gowen Cook, J., & Saurin, A. T. (2022) · The EMBO Journal · doi:10.15252/embj.2021108599 · Cited by 134
“There is also a wealth of preclinical evidence that CDK4/6 inhibitors display broad activity against a wide range of other tumour types (for reviews see (Asghar et al , 2015; O’Leary et al , 2016; Du et al , 2020)).”
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.